Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

ClinicalTrials.gov ID: NCT00515827

Public ClinicalTrials.gov record NCT00515827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens

Study identification

NCT ID
NCT00515827
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
53 participants

Conditions and interventions

Conditions

Interventions

  • Raltegravir (MK-0518) Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2007
Primary completion
Aug 31, 2008
Completion
Oct 31, 2008
Last update posted
Nov 3, 2021

2007 – 2008

United States locations

U.S. sites
20
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
Alabama Therapeutics CRS Birmingham Alabama 35294-2050
Stanford CRS Palo Alto California 94304-5350
Ucsf Aids Crs San Francisco California 94110
Harbor-UCLA Med. Ctr. CRS Torrance California 90502
University of Colorado Hospital CRS Aurora Colorado 80045
Northwestern University CRS Chicago Illinois 60611
Massachusetts General Hospital ACTG CRS Boston Massachusetts 02114
Beth Israel Deaconess Med. Ctr., ACTG CRS Boston Massachusetts 02215
Washington U CRS St Louis Missouri 63110
Cornell CRS New York New York 10011
NY Univ. HIV/AIDS CRS New York New York 10016
Columbia P&S CRS New York New York 10032-3732
Harlem ACTG CRS New York New York 10037
Univ. of Rochester ACTG CRS Rochester New York 14642
Unc Aids Crs Chapel Hill North Carolina 27514
Duke Univ. Med. Ctr. Adult CRS Durham North Carolina 27710
MetroHealth CRS Cleveland Ohio 44109
Hosp. of the Univ. of Pennsylvania CRS Philadelphia Pennsylvania 19104
Pitt CRS Pittsburgh Pennsylvania 15213-2582
University of Washington AIDS CRS Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00515827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 3, 2021 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00515827 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →